4
4TEEN4 Pharmaceuticals
4TEEN4 Pharmaceuticals develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions
About 4TEEN4 Pharmaceuticals
4TEEN4 Pharmaceuticals GmbH is a biotechnology company focused on developing innovative treatments for Cardiogenic Shock, a severe condition with high mortality rates primarily affecting patients in intensive care units. The company's flagship product, Procizumab, is a first-in-class inhibitor of the Dipeptidyl Peptidase 3 (DPP3) pathway, designed to restore cardiac function and reduce mortality. Procizumab has shown clinical proof of concept and represents a breakthrough in an area with no effective therapies currently available.
4TEEN4 Pharmaceuticals operates in the healthcare and pharmaceutical markets, targeting hospitals and medical institutions that treat acute myocardial injuries and related conditions. The company generates revenue through the development and potential commercialization of its proprietary drug, Procizumab.
Supported by funding from the European Social Fund (ESF) and the Federal State of Brandenburg, 4TEEN4 Pharmaceuticals is committed to advancing medical science and improving patient outcomes. The company employs a team of dedicated scientists and innovators, working in a dynamic small-to-medium enterprise (SME) environment.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2002
- Headquarters
- Hennigsdorf, Germany
- Employees
- 37
- Open positions
- None listed
- Dealroom signal
- 79.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Health Diagnostics, Hospital, Biotech and Pharma, Hard Tech, Horizon Europe, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Mar 2026 | $0 | — | Christ Capital | ↗ |
| SERIES COther financing | Nov 2025 | $61M | $242M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for 4TEEN4 Pharmaceuticals is 1.1K monthly website visits, up 1000% over the last three months. 4TEEN4 Pharmaceuticals's team grew 5.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
European Commission
Series A18 investors entered at this stage
Brandenburg Kapital
Wellington Partners
HBM Partners
FLORA Ventures- CACarpian
Therabel Pharma- RERubberDuck Enterprises
- CVChristiansen Ventures
- RVRother Ventures
- GÖGörlich-Gruppe
Discovery Capital- TIToucan Health Innovations
- MFMerry Fisher
- THToledo Holding
- SISoparfi Semper Paratus Industrie
- ICIcontrust
- GBGF Beteiligungs
- TVTerán Ventures
Series B and later1 investor entered at this stage
Christ Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about 4TEEN4 Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See 4TEEN4 Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.